Tag: clinical trial
Hutchmed has finished rolling-in its NDA for the treatment of refractory metastatic colorectal cancer to the US FDA.
Hutchmed (China) Limited reports that it has finished the rolling submission of a New Drug Application (NDA) to…
Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.
The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a…
Apply for the post of Clinical Research Associates and Clinical Trial Assistant at Teva Pharmaceuticals – B. Pharma/ M. Pharma/ M. Sc.
Clinical Research department in Teva supports Protocols, Bioanalysis, CDISC, Final Reports, eTMF, Data Management. It also provides bioanalysis…
Vacancy for multiple position at Stallion Laboratories Pvt. Ltd. – B. Pharma/ M. Pharma/ M. Sc.
Stallion Laboratories incorporated in 1988 as an integrated private sector Pharmaceutical Formulation Manufacturer, has acquired an unmatched record…
Apply for the position of Clinical Data Analyst at Sitero – B. Pharma/ M. Pharma/ Lifescience
Sitero is an emerging leader in Clinical services and software solutions for the life sciences industry. We have…
Apply for Regional Pharmacovigilance officer at BAYER – B. Pharma/ M. Pharma
Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in…
Apply for Medical Service Associate (Pharmacovigilance) at Accenture – B. Pharma/ M. Pharma
Global professional services provider Accenture has industry-leading expertise in digital, cloud, and security. We provide Strategy and Consulting,…
Positive findings from the second interim analysis of the phase 2 randomised trial for BX1000 are reported by Baudax Bio.
The second preplanned interim analysis of Baudax Bio, Inc.’s phase 2 trial of BX1000 for neuromuscular blockade (NMB)…
The US FDA designates Intellia’s NTLA-2002, a regenerative medicine advanced therapy to treat hereditary angioedema.
The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a…
Phase 1 patient dosing of PT886 for advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas is initiated by Phanes Therapeutics.
First patient dosed in phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb)…
Registration Form
This will close in 0 seconds
